a Helmholtz Center Munich - German Research Center for Environmental Health Comprehensive Pneumology Center, Institute of Lung Biology and Disease , Neuherberg/Munich , Germany.
b Helmholtz Center Munich - German Research Center for Environmental Health, Institute of Epidemiology 2 , Neuherberg/Munich , Germany.
Nanotoxicology. 2017 May;11(4):434-442. doi: 10.1080/17435390.2017.1306892. Epub 2017 Apr 3.
Submicrometer TiO particles, including nanoparticulate fractions, are used in an increasing variety of consumer products, as food additives and also drug delivery applications are envisaged. Beyond exposure of occupational groups, this entails an exposure risk to the public. However, nanoparticle translocation from the organ of intake and potential accumulation in secondary organs are poorly understood and in many investigations excessive doses are applied. The present study investigates the biokinetics and clearance of a low single dose (typically 40-400 μg/kg BW) of V-radiolabeled, pure TiO anatase nanoparticles ([V]TiONP) with a median aggregate/agglomerate size of 70 nm in aqueous suspension after intravenous (IV) injection into female Wistar rats. Biokinetics and clearance were followed from one-hour to 4-weeks. The use of radiolabeled nanoparticles allowed a quantitative [V]TiONP balancing of all organs, tissues, carcass and excretions of each rat without having to account for chemical background levels possibly caused by dietary or environmental titanium exposure. Highest [V]TiONP accumulations were found in liver (95.5%ID after one day), followed by spleen (2.5%), carcass (1%), skeleton (0.7%) and blood (0.4%). Detectable nanoparticle levels were found in all other organs. The [V]TiONP content in blood decreased rapidly after 24 h while the distribution in other organs and tissues remained rather constant until day-28. The present biokinetics study is part 1 of a series of studies comparing biokinetics after three classical routes of intake (IV injection (part 1), ingestion (part 2), intratracheal instillation (part 3)) under identical laboratory conditions, in order to test the common hypothesis that IV-injection is a suitable predictor for the biokinetics fate of nanoparticles administered by different routes. This hypothesis is disproved by this series of studies.
亚微米 TiO 颗粒,包括纳米颗粒部分,被越来越多地应用于各种消费品中,因为人们设想将其用作食品添加剂和药物输送应用。除了职业群体的暴露之外,这还涉及到公众的暴露风险。然而,纳米颗粒从摄入器官的转移以及在次级器官中的潜在积累情况了解甚少,而且在许多研究中都使用了过高的剂量。本研究调查了静脉注射(IV)进入雌性 Wistar 大鼠后,低单剂量(典型剂量为 40-400μg/kgBW)的 V 放射性标记、纯 TiO 锐钛矿纳米颗粒([V]TiONP)的生物动力学和清除率,其平均聚集/团聚体尺寸为 70nm,处于水悬浮液中。生物动力学和清除率从一小时到四周进行监测。放射性标记纳米颗粒的使用允许对每只大鼠的所有器官、组织、尸体和排泄物中的[V]TiONP 进行定量平衡,而不必考虑可能由饮食或环境钛暴露引起的化学背景水平。在一天后,肝脏中发现的[V]TiONP 积累最高(95.5%ID),其次是脾脏(2.5%)、尸体(1%)、骨骼(0.7%)和血液(0.4%)。在所有其他器官中均检测到可检测的纳米颗粒水平。在 24 小时后,血液中的[V]TiONP 含量迅速下降,而其他器官和组织中的分布则保持相对稳定,直到第 28 天。本生物动力学研究是一系列研究的第一部分,这些研究比较了在相同的实验室条件下,三种经典摄入途径(IV 注射(第 1 部分)、口服(第 2 部分)、气管内滴注(第 3 部分))后的生物动力学,以验证 IV 注射是通过不同途径给予纳米颗粒的生物动力学命运的合适预测因子的共同假设。这一系列研究否定了这一假设。